CorFlow to Disclose Up-To-Date Clinical Results at ‘CRT20’ for Its New Approach to Diagnosing and Potentially Treat MVO in STEMI Patients

“It is clear that there are patients who fare less well following percutaneous coronary intervention (PCI),” says Prof. Alexandra Lansky, MD. “Clinical confirmation is increasing that the presence of microvascular obstruction (MVO) is an independent predictor of a poor prognosis months and years after acute myocardial infarction (AMI),” says Prof. Alexandra Lansky, MD, Yale University Hospital.

Baar, Switzerland, February 21st 2020

CorFlow Therapeutics AG (“CorFlow”) today announced that the company will present the Controlled Flow Infusion (CoFI™) technology during the upcoming CRT conference to be held in Washington DC, USA, February 22-25.

The CorFlow (CoFI™) System has been developed for the diagnosis and serving as a treatment platform for microvascular obstruction (MVO) in patients with myocardial infarction. The technology is currently undergoing clinical trials in Europe to document the safety and feasibility during the treatment of acute heart attack patients (STEMI). MVO is documented to be an independent predictor for complications after a heart attack such as death and heart failure. According to CorFlow’s independent market research, more than 170,000 US and European patients per year will need additional diagnosis and treatment to improve the microvascular perfusion even after stent placement.

The CorFlow technology will be featured during one interview and two oral presentations during the CRT conference:

Saturday February 22nd @ 2:45PM “CARDIOTUBE: How to Diagnose and Treat Microvascular Obstruction”

Sunday February 23rd @ 10:52AM “Novel Assessment of the Coronary Microvasculature”

Sunday February 23rd @ 1:04PM “Microvascular Obstruction: Update on Diagnosis and Therapy”

Overall, the data to be presented this month during the CRT conference will contribute to consolidate the CorFlow CoFI™ technology as a solution to a major unmet need in STEMI patients, namely the need for a dedicated diagnostic and therapeutic platform to address microvascular obstruction and, eventually, improve clinical outcomes in acute heart attack patients.

Did you like this article?